Topic
11 articles from the Ganjette archive.
By May 2026, the global cannabis story is no longer easy to summarize as progress or backlash. Germany is living with its controlled model, Czechia has opened a limited home-grow path, Thailand is tightening into medical compliance, and the U.S. has moved into...
Read article →
The U.S. cannabis industry remains focused on one of its most painful structural issues: federal taxation under 280E. Even strong state operators can struggle when normal business deductions are restricted. Scheduling matters not only symbolically but operatio...
Read article →
Cannabis competition is shifting from storefront branding to supply chain strength. Cultivation quality, genetics, testing, drying, packaging, distribution, inventory control, and compliance documentation can decide whether a business survives. Maturing market...
Read article →
Cannabis enters 2025 with the first wave of legalization excitement giving way to everyday systems. In Germany, the focus is on associations, enforcement, education, medical access, and how citizens actually use the new rules. Across Europe, policymakers are w...
Read article →
The U.S. cannabis industry remains one of the most advanced and one of the most legally complicated markets in the world. State programs continue to operate, brands expand where they can, and consumers increasingly treat legal cannabis as normal. Yet federal s...
Read article →
The CBD and hemp wellness market is moving away from vague promises and into a more disciplined phase. Consumers are asking better questions about ingredients, testing, dosage, origin, and legal status. Regulators are also less tolerant of health claims that s...
Read article →
Two of the world’s most important cannabis conversations are moving in different directions. Germany is now dealing with the early reality of national reform, while the United States is focused on federal scheduling and the possible business impact of reform w...
Read article →
Germany’s new cannabis framework is now active, and the first reality check is that legalization does not mean a free-for-all market. Adult possession and home cultivation are allowed within limits, while legal supply is intentionally controlled and non-commer...
Read article →
Packaging, claims, lab testing, advertising restrictions, age gates, and product transparency are no longer boring back-office issues. They are becoming part of the brand itself. In a market where trust is fragile and regulators are watching closely, the stron...
Read article →
America’s cannabis industry is living in a contradiction: state markets continue operating, consumers are used to legal access in many places, but federal law still treats marijuana as Schedule I. Operators are not waiting for Washington to build brands and su...
Read article →
The hype cycle is no longer the story; execution is. Across Europe and North America, cannabis companies are being judged less by big promises and more by licensing, margins, patient access, retail discipline, and regulatory patience. Cannabis is becoming a no...
Read article →Newsletter
Join operators, investors and policy readers who use Ganjette as a calm, serious cannabis market desk.